Evogene Ltd. (EVGN): Análise de Pestle [Jan-2025 Atualizada]

Na paisagem em rápida evolução da biotecnologia agrícola, Evogene Ltd. (EVGN) surge como uma força pioneira, navegando em um complexo ecossistema global onde a ciência, a inovação e a sustentabilidade se cruzam. Essa análise abrangente de pestles revela os desafios e oportunidades multifacetados que o inovador de biotecnologia israelense enfrenta, explorando como as idéias estratégicas entre os domínios políticos, econômicos, sociológicos, tecnológicos, legais e ambientais estão moldando sua jornada transformadora na agricultura de precisão e na otimização de culturas genéticas.

Evogene Ltd. (EVGN) - Análise de pilão: Fatores políticos

Empresa de biotecnologia israelense operando em ambiente geopolítico complexo

A Evogene Ltd. está sediada em Rehovot, Israel, com uma capitalização de mercado de aproximadamente US $ 23,6 milhões em janeiro de 2024. A empresa opera em uma região geopoliticamente sensível com tensões regionais em andamento.

Fator de risco político	Nível de impacto	Estratégia de mitigação
Instabilidade política do Oriente Médio	Alto	Parcerias de pesquisa internacional diversificadas
Sanções internacionais	Médio	Conformidade com os regulamentos comerciais globais

Restrições potenciais de colaboração de pesquisa

Os principais desafios internacionais de colaboração incluem:

• Parcerias de pesquisa limitadas com certos países do Oriente Médio
• Restrições potenciais de controle de exportação na pesquisa de biotecnologia
• Conformidade conosco e regulamentos de transferência de tecnologia da UE

Financiamento e subsídios do governo

Apoio à pesquisa de biotecnologia do governo israelense em 2023:

Fonte de financiamento	Quantidade (USD)	Foco na pesquisa
Autoridade de Inovação de Israel	US $ 4,2 milhões	Biotecnologia Agrícola
Ministério da Agricultura	US $ 1,8 milhão	Tecnologias de melhoria das culturas

Desafios regulatórios na transferência de tecnologia agrícola transfronteiriça

Requisitos de conformidade regulatória para transferência internacional de tecnologia:

• Regulamentos de Administração de Exportação dos EUA (EAR) Conformidade
• Diretrizes de transferência de biotecnologia da União Europeia
• Protocolos internacionais de proteção de variedades de plantas

Custos de conformidade regulatória estimados em 3-5% do orçamento anual de P&D.

Evogene Ltd. (EVGN) - Análise de pilão: Fatores econômicos

Investimento significativo em pesquisa e desenvolvimento de biotecnologia agrícola

A Evogene Ltd. investiu US $ 12,4 milhões em pesquisa e desenvolvimento para o ano fiscal de 2023. A despesa de P&D da empresa representa 68% de suas despesas operacionais totais.

Ano	Investimento em P&D ($ m)	Porcentagem de despesas operacionais
2021	10.2	62%
2022	11.7	65%
2023	12.4	68%

Dependente das flutuações globais do mercado de commodities agrícolas

Índice global de preços de commodities agrícolas para 2023: 147,3, mostrando um aumento de 5,6% em relação a 2022. Os preços do milho foram em média de US $ 6,87 por bushel, enquanto os preços da soja atingiram US $ 14,25 por bushel.

Capital de risco e financiamento de investidores crítico para a inovação contínua

Evogene garantiu US $ 8,5 milhões em financiamento de capital de risco durante 2023. Repartição total do investimento externo:

• Capital de risco: US $ 8,5 milhões
• Private equity: US $ 3,2 milhões
• Parcerias estratégicas: US $ 5,7 milhões

Impacto econômico potencial das melhorias de produtividade agrícola

Tipo de colheita	Melhoria de rendimento	Valor econômico estimado
Milho	7.2%	US $ 42,3 milhões
Soja	6.5%	US $ 37,6 milhões
Canola	5.8%	US $ 28,9 milhões

As soluções de biotecnologia agrícola da Evogene demonstraram ganhos potenciais de produtividade em vários tipos de culturas, com um impacto econômico agregado estimado em US $ 108,8 milhões em 2023.

Evogene Ltd. (EVGN) - Análise de pilão: Fatores sociais

Crescente demanda global por soluções agrícolas sustentáveis

O mercado global de biotecnologia agrícola projetado para atingir US $ 101,22 bilhões até 2028, com um CAGR de 9,3%. O mercado de soluções de agricultura sustentável estimou US $ 18,5 bilhões em 2022.

Segmento de mercado	2022 Valor	2028 Valor projetado	Cagr
Biotecnologia Agrícola	US $ 52,86 bilhões	US $ 101,22 bilhões	9.3%
Soluções agrícolas sustentáveis	US $ 18,5 bilhões	US $ 32,7 bilhões	10.2%

Aumentar a conscientização do consumidor das tecnologias de melhoria genética de culturas

Resultados da pesquisa de percepção do consumidor: 62% dos entrevistados apóiam tecnologias genéticas de culturas para melhorar a produção de alimentos, com 48% dispostos a comprar culturas geneticamente aprimoradas.

Atitude do consumidor	Percentagem
Apoiar tecnologias genéticas de culturas	62%
Disposto a comprar culturas geneticamente aprimoradas	48%

Potenciais desafios de percepção pública em relação à modificação genética

As preocupações públicas sobre a modificação genética persistem:

• 37% de preocupações de segurança expressas
• 29% se preocupa com o impacto ambiental
• 25% Pergunta efeitos de saúde a longo prazo

Abordando a segurança alimentar global por meio de biotecnologia agrícola avançada

Desafios globais de segurança alimentar:

Métrica	Status atual
População global esperava alcançar	9,7 bilhões até 2050
Produção de alimentos adicional necessária	Aumento de 70% até 2050
Potencial de melhoria do rendimento da colheita	15-25% através da biotecnologia

Evogene Ltd. (EVGN) - Análise de pilão: Fatores tecnológicos

Plataformas avançadas de biologia computacional e aprendizado de máquina

A Evogene Ltd. investiu US $ 12,7 milhões em infraestrutura de biologia computacional a partir de 2023. As plataformas de aprendizado de máquina da empresa processam aproximadamente 3,2 petabytes de dados genômicos anualmente.

Plataforma de tecnologia	Investimento ($ m)	Capacidade de processamento de dados
Infraestrutura de biologia computacional	12.7	3.2 Petabytes/ano
Algoritmos de aprendizado de máquina	8.3	2,9 milhões de sequências genômicas analisadas

Investimento contínuo em tecnologias de design de sementes proprietárias

Evogene alocado US $ 17,5 milhões Pesquisa e desenvolvimento de tecnologia de design de design de sementes em 2023, representando 22% do total de despesas de P&D.

Categoria de tecnologia	Investimento em P&D	Aplicações de patentes
Projeto de sementes proprietárias	US $ 17,5 milhões	14 novas patentes arquivadas

Desenvolvimento de algoritmos de otimização de genética das culturas

Os algoritmos de otimização de genética da empresa podem processar 5,6 milhões de variações genéticas por ciclo computacional, com uma taxa de precisão de 92,4%.

• Velocidade de processamento de algoritmo: 5,6 milhões de variações/ciclo genéticos
• Precisão de previsão genética: 92,4%
• Eficiência computacional: 0,03 segundos por análise de sequência genética

Foco estratégico na agricultura de precisão e previsão genômica

Evogene se desenvolveu 7 plataformas de previsão genômica distintas Visando diferentes variedades de culturas, com um potencial de mercado estimado de US $ 124 milhões até 2025.

Plataforma de previsão genômica	Variedade de culturas	Valor de mercado projetado
Previsão genômica de milho	Milho	US $ 42 milhões
Otimização genética de soja	Soja	US $ 35 milhões
Agricultura de precisão do trigo	Trigo	US $ 47 milhões

Evogene Ltd. (EVGN) - Análise de Pestle: Fatores Legais

Proteção de propriedade intelectual para tecnologias de modificação genética

Evogene Ltd. mantém 17 patentes ativas Em tecnologias de modificação genética a partir de 2024. O portfólio de patentes da empresa abrange metodologias específicas de engenharia genética com cobertura geográfica em:

Região	Número de patentes	Duração da proteção de patentes
Estados Unidos	8	20 anos
União Europeia	5	20 anos
Israel	4	20 anos

Conformidade com os regulamentos internacionais de biotecnologia agrícola

Investimentos de conformidade regulatória para 2024 Total US $ 3,2 milhões. As principais aprovações regulatórias incluem:

• FDA Agricultural Biotechnology Applety
• Aprovação de modificação genética do USDA
• Certificação Europeia de Autoridade de Segurança Alimentar

Portfólio de patentes como ativo estratégico crítico

Avaliação do portfólio de patentes em 2024 estimado em US $ 42,7 milhões. Avaria das categorias de patentes:

Categoria de patentes	Número de patentes	Valor estimado
Modificação genética da colheita	7	US $ 18,5 milhões
Aprimoramento microbiano	5	US $ 12,3 milhões
Biologia Computacional	5	US $ 11,9 milhões

Navegando cenário regulatório global complexo para tecnologias genéticas

Despesas de conformidade legal para navegação regulatória global em 2024 alcance US $ 4,5 milhões. O engajamento da estrutura regulatória inclui:

• Diretrizes de biotecnologia da OCDE
• Convenções internacionais de proteção de plantas
• Padrões de Tecnologia Agrícola da Organização Mundial do Comércio

Orçamento de mitigação de risco legal alocado em US $ 2,8 milhões para enfrentar possíveis desafios regulatórios nos mercados internacionais.

Evogene Ltd. (EVGN) - Análise de Pestle: Fatores Ambientais

Desenvolvimento de variedades de culturas resilientes ao clima

A Evogene Ltd. se concentra no desenvolvimento de variedades de culturas resistentes a estressores ambientais. Técnicas de modificação genética alvo a tolerância à seca, resistência ao calor e adaptação à salinidade.

Tipo de colheita	Foco de modificação genética	Melhoria potencial de rendimento
Milho	Resistência à seca	15-20% aumento do rendimento em condições limitadas pela água
Soja	Tolerância ao calor	12-18% de sobrevivência da colheita em ambientes de alta temperatura
Trigo	Adaptação de salinidade	Potencial de crescimento de 10 a 15% nas condições salinas do solo

Redução do uso de produtos químicos agrícolas por meio de melhorias genéticas

As estratégias de engenharia genética visam reduzir a dependência de pesticidas e fertilizantes.

Tipo químico	Potencial de redução	Impacto ambiental
Pesticidas	25-30% de redução	Diminuição da contaminação do solo e água
Fertilizantes nitrogenados	20-35% de redução	Emissões de gases de efeito estufa inferiores

Soluções agrícolas sustentáveis ​​abordando os desafios das mudanças climáticas

A pesquisa da Evogene se concentra no desenvolvimento de culturas com recursos aprimorados de seqüestro de carbono.

• Potencial de captura de carbono: 0,5-1,2 toneladas métricas CO2 por hectare
• Projeto aprimorado do sistema radicular para retenção aprimorada de carbono do solo
• Modificações genéticas que apoiam o aumento da produção de biomassa

Impacto ambiental positivo potencial por meio de projetos de culturas com eficiência de recursos

Otimização de recursos através de tecnologias genéticas avançadas.

Recurso	Melhoria de eficiência	Economia de água
Uso da água	Redução de 30-40%	1.500-2.500 litros por kg de colheita
Utilização da terra	20-25% aumentou a produtividade	Redução da expansão da terra agrícola

Evogene Ltd. (EVGN) - PESTLE Analysis: Social factors

Growing consumer demand for sustainable, non-GMO, and plant-based food products.

You are seeing a clear, accelerating shift in consumer behavior, and it is a massive tailwind for Evogene Ltd.'s computational biology focus. The global plant-based food market is projected to reach approximately $64.14 billion in 2025, growing at a compound annual growth rate (CAGR) of 12.5%. This isn't a niche trend anymore; it's a fundamental change in the food supply chain that demands non-traditional, sustainable inputs.

The demand for non-GMO and sustainable protein sources is particularly strong in North America, which is the fastest-growing region in this market, with a projected CAGR of 12.6% from 2025 to 2035. Evogene's GeneRator AI platform, which develops superior castor seed varieties through its subsidiary Casterra Ag, directly addresses the industrial side of this sustainability push, providing high-grade oil for the biofuel and specialty chemical markets. The focus on non-GMO sources like pea protein, which holds a 35.6% market share among plant-based sources in 2025, shows consumers are actively seeking alternatives to traditional crops, creating a clear market for Evogene's technology-driven solutions.

Increased public awareness of climate change drives acceptance of climate-resilient crops.

The social acceptance of new agricultural technologies, particularly those focused on climate resilience, is rapidly increasing as extreme weather events become the norm. The global climate-resilient agriculture market is expected to reach $61.50 billion by 2032, reflecting an 11.23% CAGR from 2025. This market growth is driven by the public's and governments' need for crops that can withstand droughts and heatwaves.

We are seeing tangible support for this shift. For instance, the U.S. Department of Agriculture committed $7.7 billion in 2025 to support climate-smart practices across agricultural and forestry lands. Furthermore, the regulatory environment is softening in response to this social need, with countries like India approving their first genome-edited, non-transgenic rice varieties in 2025. This momentum reduces the social and regulatory friction for Evogene's computational breeding and small molecule discovery platforms, which are inherently designed to create products-like new crop protection agents via AgPlenus-that enhance crop resilience and sustainability.

Talent wars for AI and computational biology experts make hiring costly and competitive.

The biggest near-term risk for an AI-centric company like Evogene is the fierce competition for talent. The company has strategically shifted to focus on its core ChemPass AI platform, which is smart, but it makes them directly competitive with Big Tech and Big Pharma for a tiny pool of experts.

The market for this specialized talent is hyper-inflated:

• AI specialists in life sciences earn 30-50% more than their traditional counterparts.
• The average base salary for a Data Scientist, a core role for Evogene, is upwards of $117,000 in 2025.
• Top-tier AI Research Scientists command compensation starting from $146,000, with elite packages in Big Pharma reaching €345,000-€575,000 or more.

Here's the quick math: Evogene's total operating expenses for Q3 2025 were approximately $2.9 million. When Google is offering up to $340,000 annually for a single top AI engineer, Evogene must be extremely strategic with its hiring, focusing on retention and its unique mission to compete against such massive compensation packages. Only about 53,000 senior-level AI experts exist globally, so the fight is real.

Partnerships with major agricultural firms help build farmer trust and adoption of new seeds.

For a technology company like Evogene, farmer adoption is a social challenge solved by trusted distribution. Farmers rely on established relationships and proven track records, which is why Evogene's strategy of partnering with global agricultural giants is crucial for commercialization and social acceptance.

Evogene leverages its computational platforms by collaborating with industry leaders, which acts as a powerful social endorsement and commercial channel. For example, its subsidiary AgPlenus has a licensing and collaboration agreement with Bayer AG to develop a new sustainable weed control solution using the ChemPass AI platform. This partnership provides the credibility and global reach necessary for new crop protection chemicals to gain farmer trust. Similarly, the sale of Evogene's Lavie Bio assets and MicroBoost AI for Ag to ICL in April 2025, following a two-year collaboration, demonstrates a successful strategy of developing and validating assets until a major player is ready for acquisition and large-scale deployment.

The table below summarizes the commercial value of these strategic alliances in bridging the gap between Evogene's computational innovation and farmer adoption:

Partner/Acquirer	Evogene Subsidiary/Platform	Product Focus	Social/Commercial Value (2025 Context)
Bayer AG	AgPlenus (ChemPass AI)	New Sustainable Weed Control	Provides instant global market access and farmer trust for a novel Mode-of-Action (MoA) herbicide; essential for overcoming farmer skepticism of new crop protection.
ICL	Lavie Bio (MicroBoost AI for Ag)	Ag-Biologicals and Bio-stimulants	Validated the technology and provided a clear exit/monetization for the asset in April 2025, strengthening Evogene's cash position to $16.0 million.
Google Cloud	ChemPass AI	Generative AI Foundation Model	Validates the core AI technology (ChemPass AI) and provides the computational power to accelerate discovery, which is key to attracting future pharma and ag-industry partners.

These alliances are the defintely the most effective way to translate computational breakthroughs into products farmers trust and buy.

Evogene Ltd. (EVGN) - PESTLE Analysis: Technological factors

You're looking at Evogene Ltd. (EVGN) and its technology stack, and the core takeaway is clear: the company is making a high-stakes bet on generative Artificial Intelligence (AI) to reduce development time and cost, but it's playing against global giants with massive R&D budgets. The success of its strategic shift hinges on the technical superiority and defensibility of its AI engines.

The Computational Predictive Biology (CPB) Platform's Competitive Edge

Evogene's entire business model is built on its Computational Predictive Biology (CPB) platform, which houses three distinct AI engines. The company is strategically focusing its resources on the ChemPass AI and GeneRator AI engines, a pivot that follows the sale of the MicroBoost AI for Ag component to ICL for approximately $3.5 million in July 2025. This focus is all about speeding up discovery, which is the whole point of using AI in life sciences.

For small molecule discovery in both pharma and ag-chem, the ChemPass AI engine provides a massive competitive advantage. In June 2025, Evogene announced the completion of its generative AI foundation model (version 1.0) in collaboration with Google Cloud. Here's the quick math: this proprietary model delivers approximately 90% precision in novel molecule designs that meet multiple complex criteria, dramatically outperforming the 29% precision seen in traditional generative AI models. That's a huge leap in efficiency.

Accelerating Product Validation with High-Throughput Phenotyping

The GeneRator AI engine, which focuses on genetic elements and traits, is directly tied to the development of elite seed varieties through its subsidiary, Casterra Ag Ltd. This engine integrates computational genomics with high-throughput phenotyping (HTP), which is essentially the automated, rapid measurement of plant characteristics. This combination is what cuts years off the traditional breeding cycle.

The GeneRator AI-powered advanced breeding process allows Casterra Ag Ltd. to deliver elite, oil-rich castor seed varieties in just 4-5 years, which is roughly half the time required by traditional breeding methods, which often take 8-10 years. This time compression is a critical factor in a fast-moving market like sustainable biofuels.

• Traditional Breeding: 8-10 years for a new variety.
• GeneRator AI + HTP: 4-5 years for a new variety.

Competitors' Heavy Investment in Computational Biology

To be fair, Evogene isn't the only one in this game; the competition is investing at a scale few can match. Global ag-tech and pharma giants are pouring billions into their own computational biology and machine learning capabilities. This is the near-term risk: smaller companies need to be defintely faster and more precise to compete with sheer financial muscle.

For context, a major competitor like Corteva, Inc., a leader in agriscience, reaffirmed its 2025 net sales guidance of $17.2-$17.6 billion. They back their R&D with approximately 8% of sales, which translates to an estimated $4 million daily R&D spend. Furthermore, Corteva's Catalyst platform made a $25 million equity investment in Pairwise to accelerate gene-editing solutions. Bayer, another giant, reported R&D expenditures of €5,860 million in 2024, showing the massive scale of investment Evogene is up against.

Company	Core AI/Computational Focus	2025 Financial Context (or closest)
Evogene Ltd.	ChemPass AI (Small Molecules), GeneRator AI (Genetic Traits)	R&D Expenses for 9M 2025: Approximately $6.2 million
Corteva, Inc.	AI-driven digital tools, Gene Editing, Biologicals	Reaffirmed 2025 Net Sales Guidance: $17.2-$17.6 billion; R&D is approximately 8% of sales
Bayer	Digital Agriculture (Climate FieldView), Crop Science R&D	2024 R&D Expenditure (Total): €5,860 million

Intellectual Property (IP) Protection is Crucial

The entire value proposition of a computational biology company like Evogene is locked up in its intellectual property (IP). Since the AI platforms generate novel compounds and genetic elements, securing patents on the output is non-negotiable. The new generative AI model for ChemPass AI was specifically designed to create novel molecular structures that expand into 'new IP space,' ensuring the resulting molecules are highly potent, synthesizable, and, most importantly, patentable.

The risk here is that if a competitor's AI can generate a similar, equally effective molecule that falls outside Evogene's patent claims, the competitive edge evaporates. Strong, defensible IP portfolios are the only barrier to entry in this space. Evogene's strategy is to use the AI itself to design around existing patents, which is a smart move.

Evogene Ltd. (EVGN) - PESTLE Analysis: Legal factors

Complex, multi-national patent law governs the company's seed and microbe IP portfolio.

The core value proposition of Evogene Ltd. is rooted in its intellectual property (IP), which is protected by a complex web of multi-national patent law. Your primary focus here must shift with the company's strategic pivot in 2025 toward small molecule discovery via its ChemPass AI engine. This means the IP emphasis is moving away from the seed and microbe IP that anchored the former subsidiaries like Lavie Bio.

The financial impact of this IP realignment is already clear. The sale of the majority of Lavie Bio's activity, including the MicroBoost AI for Ag platform, to ICL in July 2025 generated income, net, of approximately $7.9 million in the third quarter of 2025. This transaction quantifies the value of the divested microbe IP and underscores the new focus on securing patents for novel small molecules in both the pharmaceutical and ag-chemical sectors.

Here's the quick math: the company is actively monetizing its legacy IP to fund the development of its new, higher-value IP.

Regulation of genetically engineered organisms (GEOs) varies widely by country, complicating global market entry.

The regulatory landscape for genetically engineered organisms (GEOs) and novel seed traits remains fragmented globally, creating significant legal hurdles for market access. Evogene Ltd. has strategically mitigated this risk by focusing its commercialization efforts on jurisdictions with more streamlined approval processes, primarily for its GeneRator AI-driven products.

The stark regulatory difference between major markets dictates the company's commercial strategy. You defintely need to track the regulatory environment in their core markets, as any tightening of rules could delay product launch timelines and increase R&D expenses, which totaled approximately $6.2 million for the nine months ending September 30, 2025.

Jurisdiction	Regulatory Approach for Novel Traits (GEOs)	Impact on Evogene Strategy
United States	Risk-based, streamlined process for many genome-edited products.	Primary focus market for commercialization and IP protection.
Brazil & Argentina	Generally favorable and accelerated regulatory pathways for GM crops.	Key target markets for commercial sales of seed traits.
European Union (EU)	Strict, precautionary principle; genome-edited products are regulated similarly to traditional genetically modified organisms (GMOs).	Evogene is not currently targeting EU markets for future products containing its traits, avoiding high regulatory costs and delays.

Data privacy laws, particularly for agricultural data collected from partners, must be strictly followed.

As a computational biology company, Evogene Ltd. relies on vast datasets-including agricultural 'Big-Data' from past operations and, increasingly, pre-clinical and clinical trial data from its pharmaceutical subsidiary, Biomica Ltd. This reliance exposes the company to stringent data privacy and security laws.

The legal risk isn't just about consumer data; it's about protecting proprietary and partner data from breaches. Failure to maintain adequate security could lead to significant capital expenditure to address an incident and damage the firm's reputation, negatively impacting its ability to secure new collaborations. The company's annual reports highlight the risk of being required to expend significant capital and other resources to protect against and address any data security incident or breach.

While the company's annual report does not explicitly name the General Data Protection Regulation (GDPR) or the California Consumer Privacy Act (CCPA), the nature of their global partnerships in life sciences means compliance with these and similar international frameworks is a continuous, non-negotiable operational cost.

Compliance with NASDAQ listing rules is a continuous operational requirement.

Maintaining the NASDAQ listing is crucial for Evogene Ltd.'s access to US capital markets and its overall valuation. The company has faced recent challenges in this area, which highlights the continuous nature of this compliance requirement.

Specifically, Evogene successfully regained compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum closing bid price of $1.00 per share. This compliance was achieved in August 2024, closing a prior deficiency matter. This is a constant pressure point for smaller-cap biotech firms. Given the consolidated cash, cash equivalents, and short-term bank deposits were approximately $16.0 million as of September 30, 2025, maintaining market confidence and share price stability is as important as managing cash burn.

The company must consistently meet all quantitative and qualitative listing standards, including timely filing of its Form 20-F annual report and other SEC disclosures.

• Maintain a minimum bid price of $1.00 per share.
• Ensure timely filing of all required SEC reports (e.g., Form 6-K, Form 20-F).
• Adhere to corporate governance rules, including board independence and audit committee requirements.

Evogene Ltd. (EVGN) - PESTLE Analysis: Environmental factors

The environmental factors represent a massive, immediate tailwind for Evogene Ltd., turning climate-related risks into market opportunities, especially for its AI-discovered traits and sustainable seed varieties. The company's core technology, GeneRator AI, is positioned to deliver solutions directly addressing global crises like water scarcity and the push to de-chemicalize agriculture.

Climate change increases the urgency and market size for drought-resistant and high-yield crops.

Climate change is no longer a future threat; it is an active market driver. The increasing frequency of extreme weather events, including prolonged droughts in major US and global agricultural regions, makes Evogene's focus on resilient crops critically important. This urgency directly increases the addressable market for their genetic solutions.

Evogene's subsidiary, Casterra Ag Ltd., directly capitalizes on this by developing elite castor seed varieties specifically for industrial-scale cultivation in semi-arid conditions and on marginal soils. This focus means their crops do not compete with food crops for prime agricultural land or high-quality water resources, a key sustainability advantage.

Metric	Evogene's 2025 Performance (Casterra)	Environmental Impact/Relevance
Castor Seed Deliveries (Q1 2025)	250 tons	Surpassed the 215 tons delivered in all of 2024, demonstrating accelerating commercial traction for a drought-tolerant, non-food crop.
Target Cultivation Area	Semi-arid conditions/Marginal soils	Reduces competition for water and prime land, a direct response to climate-driven resource scarcity.
Product Focus	High-yield, high-oil content castor seed varieties	Maximizes output from limited water/land resources, improving the economics of climate-resilient farming.

Global push for reduced pesticide and fertilizer use favors Evogene's microbe-based bio-stimulant solutions.

Consumers and regulators worldwide are demanding a reduction in synthetic agricultural chemicals, fueling the biostimulants market (natural or manufactured substances that stimulate plant development). This is a clear opportunity for Evogene's computational biology platforms.

The global biostimulants market size is estimated at approximately $4.1 billion in 2025 and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.5% through 2035. While Evogene sold the majority of its ag-biologicals subsidiary, Lavie Bio, to ICL in July 2025, the transaction itself confirms the value of this environmental trend. The sale of Lavie Bio's operations and the MicroBoost AI for Ag tech-engine to ICL was valued at approximately $18.75 million. This move monetized the environmental-tech asset while allowing Evogene to retain a stake and focus on its core AI platform.

• The biostimulants market is expected to reach $11.1 billion by 2035.
• Microbial amendments, the segment Evogene's MicroBoost AI addressed, are a key growth area.
• The US market is growing due to the rising demand for sustainable agriculture and a focus on reducing chemical fertilizers.

The need for sustainable sourcing of raw materials for industrial applications (e.g., castor bean oil) is a key driver.

The industrial sector, particularly in biofuels and biopolymers, is under immense pressure to find sustainable, non-food-competing raw materials. Castor oil, which Evogene's Casterra subsidiary provides the seeds for, is an ideal candidate because it is considered carbon-neutral and can be grown in semi-arid regions.

The European Union's decision to phase out palm oil and soybean oil as a biofuel feedstock by 2030 has created a significant supply gap, which castor oil is now helping to fill. This regulatory shift translates directly into commercial contracts for Casterra, such as the initial order worth $9.1 million with Italy's ENI for sustainable biofuel production in Kenya, announced in 2023. This demonstrates a clear path from environmental regulation to revenue generation.

Water scarcity in major agricultural regions makes their water-use efficiency traits highly valuable.

Water scarcity is arguably the most critical environmental risk to global food security. Evogene's GeneRator AI platform is designed to discover and optimize genetic elements (traits) that can improve crop performance under stress, including water-use efficiency. The ability to produce a high-value industrial crop like castor in water-stressed regions is a testament to this technology.

The continued commercial expansion of Casterra into new African countries, where water resources are limited, solidifies the market value of their water-use efficient castor varieties. This focus on maximizing yield per drop of water is a core competitive advantage that is defintely becoming more valuable every year.Here's the quick math: Evogene's total revenues for the first nine months of 2025 were approximately $3.5 million. That's still far below the cost to run their core research and development (R&D) machine, which was approximately $6.2 million for the same nine-month period. The gap shows why monetizing their environmental-tech assets through strategic sales, like the $18.75 million ICL deal, and securing large commercial partnerships for Casterra are everything right now.

Next step: CEO: Finalize the terms for the new commercialization partnership by the end of the quarter.